BICO Group
44.62 SEK -6.5%2 investors are following this company
BICO Group is active in medical technology. The company specializes in bio convergence and provides technology, products, and services for biology. With a focus on the application areas bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets technology that enables researchers to grow cells in 3D environments, conduct drug screening, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.
Revenue
2.25B
EBIT %
-64.44 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BICO
Daily low / high price
44.1 / 48
SEK
Market cap
3.15B SEK
Turnover
5.08M SEK
Volume
112K
Latest videos
Financial calendar
Interim report
2024-05-07
General meeting
2024-05-20
Interim report
2024-08-20
Interim report
2024-11-13
Annual report
2025-02-19
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Erik Gatenholm | 13.6 % | 20.5 % |
Sartorius Lab Holding GmbH | 10.1 % | 8.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Invitation to the presentation of BICO’s interim report Q1, 2024
Anders Fogelberg appointed as Chief Commercial Officer for BICO Group AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools